Table 2. Odds ratio (adjusted for age and sex) for symptomatic AD vs. asymptomatic AD for each SNP.
| Gene | SNP | Risk allele | OR from IGAP | OR (95% CI) | OR (95% CI) for APOE ε4 carriers (1 or 2 ε4 alleles) | OR (95% CI) for APOE ε4 non-carriers (0 ε4 alleles) |
|---|---|---|---|---|---|---|
| ABCA7 | rs4147929 | A | 1.15 | 1.66 (1.03,2.85) | 1.25 (0.55,3.34) | 1.81 (1.00,3.57) |
| BIN1 | rs6733839 | T | 1.22 | 0.96 (0.63,1.47) | 1.02 (0.42,2.67) | 1.06 (0.65,1.76) |
| CASS4 | rs7274581 | T | 0.88a | 1.12 (0.59,1.97) | 1.53 (0.46,3.98) | 1.03 (0.46,2.09) |
| CD2AP | rs10948363 | G | 1.10 | 0.73 (0.50,1.09) | 0.35 (0.16,0.74) | 0.99 (0.62,1.62) |
| CD33 | rs3865444 | C | 0.94a | 1.26 (0.86,1.82) | 1.28 (0.59,2.69) | 1.44 (0.93,2.23) |
| CELF1 | rs10838725 | C | 1.08 | 0.99 (0.67,1.47) | 0.70 (0.34,1.50) | 1.14 (0.71,1.87) |
| CLU | rs9331896 | T | 0.86a | 0.83 (0.55,1.25) | 1.18 (0.47,2.86) | 0.73(0.44,1.18) |
| CR1 | rs6656401 | A | 1.18 | 1.46 (0.87,2.57) | 1.56 (0.59,5.35) | 1.44 (0.78,2.83) |
| DSG2 | rs8093731 | C | 0.73a | 0.96 (0.05,5.41) | NA | 0.94 (0.05,5.98) |
| EPHA1 | rs11771145 | G | 0.90a | 0.96 (0.65,1.40) | 1.29 (0.58,2.75) | 0.88 (0.56,1.37) |
| FERMT2 | rs17125944 | C | 1.14 | 1.69 (0.81,4.10) | 3.05 (0.60,55.84) | 1.41 (0.63,3.77) |
| HLA-DRB5/HLA-DRB1 | rs9271192 | C | 1.11 | 1.01 (0.68,1.52) | 0.93 (0.42,2.19) | 1.03 (0.65,1.68) |
| INPP5D | rs35349669 | T | 1.08 | 0.88 (0.61,1.28) | 1.07 (0.49,2.28) | 0.75 (0.48,1.15) |
| MAPT | rs393152 | A | NA | 2.18 (1.26,3.77) | 3.73 (1.30,11.76) | 1.77 (0.92,3.42) |
| MEF2C | rs190982 | A | 0.93a | 1.24 (0.84,1.82) | 1.03 (0.44,2.34) | 1.15 (0.74,1.81) |
| MS4A4A | rs983392 | A | 0.90a | 1.29 (0.88,1.90) | 1.57 (0.72,3.43) | 1.19 (0.75,1.90) |
| NME8 | rs2718058 | A | 0.93a | 0.77 (0.51,1.14) | 0.89 (0.38,1.98) | 0.74 (0.45,1.18) |
| PICALM | rs10792832 | G | 0.87a | 1.16 (0.79,1.69) | 1.03 (0.45,2.27) | 1.15 (0.75,1.77) |
| PTK2B | rs28834970 | C | 1.10 | 1.22 (0.85,1.78) | 1.38 (0.68,3.02) | 1.10 (0.71,1.72) |
| SLC24A4/RIN3 | rs10498633 | G | 0.91a | 1.24 (0.82,1.86) | 1.50 (0.63,3.36) | 1.15 (0.70,1.84) |
| SORL1 | rs11218343 | T | 0.77a | 1.72 (0.62,4.08) | 2.99 (0.63,10.64) | 1.45 (0.32,4.97) |
| ZCWPW1 | rs1476679 | T | 0.91a | 1.31 (0.87,1.95) | 2.98 (1.34,6.86) | 1.04 (0.62,1.69) |
ORs for IGAP are for minor allele count. ORs for the current study are for risk allele count. ORs denoted by “a” indicate when the major allele is the risk allele. Hence, ORs denoted by “a” would be expected to be in the opposite direction for this study compared with IGAP.
Note: ORs should be interpreted as the odds of symptomatic vs. asymptomatic for an increase of one risk allele. For example, the odds of symptomatic AD for rs6656401 is 18% higher for a participant with one risk allele vs. no risk alleles. Due to missing values, the number of participants in each cell varies: All participants: max=589, min=473; APOE ε4 carriers: max=292, min=234; APOE ε4 non-carriers: max=297, min=239 for all SNPs except the one associated with MAPT. For MAPT, n=345 for all participants, n=174 for APOE ε4 carriers, and n=171 for APOE ε4 non-carriers. SNPs in bold were significant at the 0.05 alpha level.
IGAP= International Genomics of Alzheimer's Project; NA= Not applicable; data too sparse for analysis.